Skip to main content

Table 2 Baseline characteristics of bio-naïve AS patients starting a first TNFi in 2006–2015

From: Biological treatment of ankylosing spondylitis: a nationwide study of treatment trajectories on a patient level in clinical practice

Baseline characteristics 2006–2015 cohort 2006–2010 subset-cohort
Total number 2590 1167
Sex, men (%) 1827 (71) 838 (72)
Age, mean (sd) 44 (13.2) 44 (12.8)
Disease duration 16 (12.3) 16 (11.8)
csDMARD (concomitant use), n (%) 634 (24) 384 (33)
NSAID (concomitant use), n (%) 2136 (82) 972 (83)
Peripheral diseasea 464 (18) 195 (17)
Type of TNFi
 Infliximab, n (%) 910 (35) 478 (41)
 Adalimumab, n (%) 782 (30) 405 (35)
 Golimumab, n (%) 329 (13) 9 (1)
 Etanercept, n (%) 483 (19) 273 (23)
 Certolizumab pegol, n (%) 86 (3) 2 (0)
Extra-articular SpA manifestations
 Anterior uveitis, n (%) 711 (27) 308 (26)
 Psoriasis, n (%) 156 (6) 65 (6)
 Inflammatory bowel disease, n (%) 179 (7) 95 (8)
  1. a≥ 1 swollen joint recorded at a visit in the year prior to TNFi start
  2. csDMARDs conventional synthetic disease-modifying anti-rheumatic drugs, NSAID non-steroidal anti-inflammatory drugs, TNFi tumour necrosis factor alpha inhibitors, SpA spondyloarthritis